<?xml version="1.0" encoding="UTF-8"?>
<modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
  <mods>
    <titleInfo>
      <title>Clashes between subsidized and private ACT markets : when administrative, Global Health, and marketing regulations collide</title>
    </titleInfo>
    <name type="personnal">
      <namePart type="family">Baxerres</namePart>
      <namePart type="given">Carine</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Pourraz</namePart>
      <namePart type="given">J.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="local">bookSection</genre>
    <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <physicalDescription>
      <internetMediaType>text/pdf</internetMediaType>
      <digitalOrigin>reformatted digital</digitalOrigin>
      <reformattingQuality>access</reformattingQuality>
    </physicalDescription>
    <abstract>The supply of artemisinin-based combination therapies (ACTs) in Benin and Ghana is made up of both subsidized ACTs produced by European multinationals or Asian generics companies and ACTs produced for private markets by Asian or African manufacturers. Global Health programs significantly structure pharmaceutical markets in the Global South, including in countries where distribution is largely liberalized, as in the case of Ghana. Thus, the subsidized drugs they distribute are abundantly found and take precedence over local production, as we will show through the study of a pilot program, the Affordable Medicines Facility-malaria (AMFm), and its effects on the Ghanaian private market. Faced with this, Asian ACT producers, as well as local and European ones, are deploying marketing strategies to conquer unsubsidized private markets and reach consumers as closely and directly as possible. They are supported in this by their representatives as well as by distributors and retailers, in both urban and rural areas, who rely in particular on the socioeconomic positions of consumers. By analyzing these ACT markets, this chapter shows how companies have to maneuver to capture market share between the administrative regulations implemented by national and transnational actors and the marketing regulations developed by the firms themselves.</abstract>
    <targetAudience authority="marctarget">specialized</targetAudience>
    <subject authority="local">
      <geographic>BENIN</geographic>
      <geographic>GHANA</geographic>
    </subject>
    <classification authority="local">050MEDECI</classification>
    <classification authority="local">094COMIN</classification>
    <classification authority="local">056POLSAN</classification>
    <relatedItem type="host">
      <titleInfo>
        <title>Understanding drugs markets :  an analysis of medicines, regulations and pharmaceutical systems in the Global South</title>
      </titleInfo>
      <name type="personnal">
        <namePart type="family">Baxerres</namePart>
        <namePart type="given">Carine</namePart>
        <role>
          <roleTerm type="text">ed.</roleTerm>
          <roleTerm type="code" authority="marcrelator">edt</roleTerm>
        </role>
        <affiliation>IRD</affiliation>
      </name>
      <name type="personnal">
        <namePart type="family">Cassier</namePart>
        <namePart type="given">M.</namePart>
        <role>
          <roleTerm type="text">ed.</roleTerm>
          <roleTerm type="code" authority="marcrelator">edt</roleTerm>
        </role>
        <affiliation>IRD</affiliation>
      </name>
      <part>
        <extent unit="pages">
          <list>136-156</list>
        </extent>
      </part>
      <originInfo>
        <place type="text">
          <placeTerm>Oxon (GBR)</placeTerm>
        </place>
        <publisher>Routledge</publisher>
        <place type="text">
          <placeTerm>New-York</placeTerm>
        </place>
        <dateIssued key="date">2021</dateIssued>
      </originInfo>
    </relatedItem>
    <relatedItem type="series">
      <titleInfo>
        <title>Routledge Studies in the Sociology of Health and Illness</title>
      </titleInfo>
    </relatedItem>
    <identifier type="uri">https://www.documentation.ird.fr/hor/fdi:010084099</identifier>
    <identifier type="doi">10.4324/9780429329517-6</identifier>
    <identifier type="isbn">978-1-03-204313-5</identifier>
    <location>
      <shelfLocator>[F A010084095]</shelfLocator>
      <url usage="primary display" access="object in context">https://www.documentation.ird.fr/hor/fdi:010084099</url>
      <url access="row object">https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2022-06/010084099.pdf</url>
    </location>
    <recordInfo>
      <recordContentSource>IRD - Base Horizon / Pleins textes</recordContentSource>
      <recordCreationDate encoding="w3cdtf">2022-01-18</recordCreationDate>
      <recordChangeDate encoding="w3cdtf">2025-02-24</recordChangeDate>
      <recordIdentifier>fdi:010084099</recordIdentifier>
      <languageOfCataloging>
        <languageTerm authority="iso639-2b">fre</languageTerm>
      </languageOfCataloging>
    </recordInfo>
  </mods>
</modsCollection>
